Die Fundamentaldaten des Unternehmens sind relativ sehr gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. Trotz einer guten Leistung an den Aktienmärkten und überlegenen Fundamentaldaten unterstützen die technischen Indikatoren den aktuellen Trend nicht. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Firefly Neuroscience Inc Bewertung
Zugehörige Informationen
Branchenrang
244 / 469
Gesamtwertung
464 / 4706
Branche
Software & IT-Dienstleistungen
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
0
Analysten
--
Aktuelles Rating
--
Kursziel
--
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Firefly Neuroscience Inc Highlights
HöhepunkteRisiko
Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company dedicated to developing neuroscientific solutions that enhance outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics (BNA) software platform (the BNA Platform) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD). BNA, utilizing AI and an extensive proprietary electroencephalogram (EEG) database, combines the automatic analysis of Event Related Potentials (ERPs), spectral EEG and behavioral performance data for a comprehensive, and objective data-driven brain health evaluation. The BNA Platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition).
Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company dedicated to developing neuroscientific solutions that enhance outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics (BNA) software platform (the BNA Platform) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD). BNA, utilizing AI and an extensive proprietary electroencephalogram (EEG) database, combines the automatic analysis of Event Related Potentials (ERPs), spectral EEG and behavioral performance data for a comprehensive, and objective data-driven brain health evaluation. The BNA Platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition).